ProQR Therapeutics N.V (NASDAQ:PRQR) does about 1.05M shares in volume on a normal day but saw 2151384 shares change hands in the recent trading day. The company now has a market cap of 353.67M USD. Its current market price is $4.33, marking a decrease of -3.56% compared to the previous close of $4.49. The 52 week high reached by this stock is $4.62 whilst the lowest price level in 52 weeks is $1.11. The script in recent trading has seen the stock touch a high of $5 and a low of $2.
ProQR Therapeutics N.V (PRQR) has a 20-day trading average at $2.19 and the current price is -6.28% off the 52-week high compared with 290.09% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.06 and its 200-day simple moving average is $2.01. If we look at the stock’s price movements over the week, volatility stands at 33.61%, which decreases to 14.06% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 86.58 to suggest the stock is overbought.
5 analysts observing the ProQR Therapeutics N.V (PRQR) stock have set the 12-month price targets for the company’s shares at between $2 and $5. The consensus objective for the share price is $4.33. The median price target is -15.47% away from the current levels at $3.75.
FactSet Research has provided data showing that 5 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 4 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 08, 2023 when Chardan Capital Markets upgraded the stock to “Buy” and issued a price target of $2. JMP Securities also upgraded the stock to “Mkt Outperform” from Mkt Perform on March 30, 2023 at a price target of $1.50-$5. Cantor Fitzgerald upgraded its price target at $0.80-$5.
The current price level is 97.36%, 110.39%, and 115.43% away from its SMA20, SMA50, and SMA200 respectively, with the PRQR price moving below the 50-day SMA on current market day. ProQR Therapeutics N.V (PRQR) stock is up 134.05% over the week and 143.26% over the past month. Its price is 118.69% year-to-date and 225.56% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/30/2024, with the company’s earnings per share (EPS) of -0.08 above consensus estimates by 0.01. The company’s next earnings report forecasts estimating quarterly EPS at -0.11 and -0.33 for whole year. Expected sales for next quarter are $5.53M, which analysts say will come at $28.49M for the current fiscal year and next year at $25.5M. In addition, estimates put the company’s current quarterly revenue at an average of $12.04M.
Its 12-month price target is $3.75. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $2, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $5.
Outstanding shares total 78.46M with insiders holding 18.22% of the shares and institutional holders owning 31.20% of the company’s common stock. The company has a return on investment of -47.37% and return on equity of -50.85%. The beta has a value of 0.39. Price to book ratio is 10.04 and price to sales ratio is 21.25.
